New Hospital Cost Center for Reporting Allogeneic HCT Cell Aquisition
CMS has released new instructions for reporting acquisition
costs associated with allogeneic HCT on the annual cost report:
Line 77--Effective for services
rendered on or after January 1, 2017, enter the hospital acquisition costs for
allogeneic stem cell transplants (when stem cells are obtained from a donor
rather than from the recipient) as defined in CMS Pub. 100-04, chapter 4,
§231.11. Do not include costs for autologous transplants (when transplanted
stem cells are obtained from the recipient (CMS Pub. 100-04, chapter 4,
Line 77, specific
to allogeneic cell acquisition, is found on the hospital cost report form
CMS-2552-10 and replaces line 112 (other organ acquisition) as the cost center
for reporting all donor search and cell acquisition costs associated with
revenue code 0815. Addition of cost center 77 will allow CMS to more accurately
capture acquisition costs specific to allogeneic HCT.
Download Medicare Reimbursement Manual
Chapter 40 (T13) – Hospital & Hospital Health Care (Form CMS-2552-10)
Choosing Wisely Top 5 Recommendations for HCT
The American Society for Blood and Marrow Transplantation
and the Canadian Blood and Marrow Transplant Group joined together to release
five recommendations for the Choosing Wisely initiative of the American Board
of Internal Medicine (ABIM) Foundation. Choosing Wisely recommendations were
created to “spark conversations between providers and patients” in an effort to
promote transparency and engagement.
Choosing Wisely Top 5 for HCT.
Learn more about Choosing Wisely.
Ask Members of Congress to Protect Access to Transplant
We are still working very hard on getting H.R. 4215
passed, and we still need your support. Please Take Action by asking your Members of Congress to support H.R. 4215. This
legislation would require the CMS to pay for cell acquisition on a reasonable cost basis and separately from the
payment for the transplant hospital stay. The current payment of approximately
$65,000 inadequately covers both cell acquisition and the transplant hospital
stay. While there is not yet a Senate companion bill to H.R. 4215, it is still
important to let your Senators know how important it is that they fix this payment
issue before the April release of the Hospital Inpatient Prospective Payment
System (IPPS) Proposed Rule. Your support of H.R. 4215 ensures that Medicare
beneficiaries continue to have access to life-saving transplant.
2018 BMT Tandem Meetings Highlight - CMS Super Session
If you are attending the BMT Tandem Meeting this year in Salt Lake City,
don’t forget to add the CMS Super Session to your meeting schedule. This
session, part of the Administrative Director’s Conference track, will provide
need-to-know updates on Medicare coverage, clinical trials, cost center
reporting, and legislative efforts to improve reimbursement. And be sure to
pick up new billing and coding resources! Mark
your calendar: Thursday, February 22,
2018 from 10:30 a.m. – 12 noon (MST) in Room 251, Salt Palace Convention Center.
Forward to a Friend
Please forward this email to others who would benefit from this information. If this email was forwarded to you, we invite you to subscribe.
If you have any questions or need additional information, please contact the Payer Policy Team at PayerPolicy@nmdp.org. All of our resources are available on our website: Network.BeTheMatchClinical.org/Reimbursement.